Directions in the Treatment of Marginal Zone Lymphoma
Meeting Series
Meeting Series

Directions in the Treatment of Marginal Zone Lymphoma

Not a member of My prIME? Join now for instant access.

Hone your knowledge of marginal zone lymphoma (MZL)! Join expert faculty and colleagues for an engaging, interactive discussion on MZL tumor biology and new treatments for the disease, with a focus on the application of clinical information to your practice.

CME

CME

1.0 AMA PRA Category 1 Credit

CE

CE

1.0 Contact Hour

This meeting series has ended.

5 min Hematology Guru: How well do you know marginal zone lymphoma?
15 min Marginal zone lymphoma 101: Diagnosis and tumor biology
5 min Questions from the audience
20 min 2017 and beyond: What does the future hold for marginal zone lymphoma?
5 min Questions from the audience
5 min Hematology Guru: How well do you know marginal zone lymphoma?
5 min Conclusions and prIME Points™

Chair

  • Christopher Flowers, MDEmory Winship Cancer Institute
    Atlanta, Georgia, United States

Faculty

  • Jacqueline Barrientos, MD, MSNorthwell Health
    Lake Success, New York, United States
  • Nishitha Reddy, MDVanderbilt-Ingram Cancer Center
    Washington, DC, United States

This educational activity is specifically designed to meet the needs of hematologists, oncologists, pathologists, registered nurses, and other healthcare professionals involved in the treatment of patients with marginal zone lymphoma.

After successful completion of this educational activity, participants should be able to:

  • Describe the unique biology and etiology of marginal zone lymphoma subtypes and how this influences diagnosis, prognosis, and therapeutic targeting
  • Employ appropriate treatment approaches for patients with marginal zone lymphoma based on current treatment guidelines and emerging clinical trial data
  • Evaluate recent clinical data investigating the efficacy and safety of novel treatment approaches for marginal zone lymphoma and the potential future role for these strategies in patient care

This activity is supported by educational grants from Celgene; Pharmacyclics LLC, an AbbVie Company; and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Continuing Education

Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Directions in the Treatment of Marginal Zone Lymphoma - prIME Oncology

Annenberg Center for Health Sciences at Eisenhower designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Annenberg Center for Health Sciences is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

A maximum of 1.0 contact hour may be earned for successful completion of this activity.

Provider

This activity is provided by the Annenberg Center for Health Sciences at Eisenhower.

Sunshine Act

prIME Oncology complies with all Sunshine Act reporting requirements as outlined by CMS and applicable manufacturers and with EFPIA Disclosure Code reporting requirements.

Disclosures

Disclosure of Relevant Financial Relationships

prIME Oncology assesses the relevant financial relationships of its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.